Long Term Incentive Plan 2022 Performance Share Awards

Paris, France and Camberley, UK – 4 February 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it is launching a new Performance Share Awards programme for executive management as part of its new Long Term Incentive Plan (“LTIP”). This new LTIP replaces the previous phantom share

Visit Page

Strategy and Full Year 2021 Trading Update and Interview with David Allmond

Full year revenue and EBITDA in line with expectationsCommitted to becoming a leading, global clinical diagnostics company Paris, France and Camberley, UK – 25 January 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2021, together with a strategy

Visit Page

Approval of COVID-19 test in the UK under CTDA legislation

Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXTGROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,announces that, further to the announcement on 2 November 2021, the Company’sgenesig® COVID-19 Real-Time PCR test has been approved in the UK under the UK HealthSecurity Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment)Regulations 2021

Visit Page